Celcuity (CELC) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Celcuity (CELC) has outperformed Legend Biotech (LEGN) over the past year, gaining 33.4% versus a loss of 39.1%. Over five years, CELC leads with a +260.8% price change compared with -63.2% for LEGN. Legend Biotech is the larger company by market cap ($3.72 billion vs $3.22 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | LEGN |
|---|---|---|
| Share price | $65.78 | $19.12 |
| Market cap | $3.22B | $3.72B |
| 1-day change | -7.68% | +2.14% |
| YTD return | -34.16% | -12.05% |
| 1-year return | +33.43% | -39.13% |
| 5-year return | +260.82% | -63.17% |
| Forward P/E | — | 18.21 |
| EPS (TTM) | $-4.17 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $37.50 |
| 52-week low | $45.03 | $16.24 |
| Distance from 52-week high | -56.44% | -49.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +138.54% | +143.20% |
| Average volume | 1.19M | 2.35M |
| Shares outstanding | 48.93M | 194.49M |
| Employees | 155 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELC has outperformed LEGN by 72.6 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
CELC vs LEGN FAQ
Which is bigger, Celcuity or Legend Biotech?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.72B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or LEGN?
CELC returned +33.43% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Legend Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Pharmaceutical Preparations for Legend Biotech.